

**UNITED STATES COURT OF APPEALS  
FOR THE DISTRICT OF COLUMBIA CIRCUIT**

JUUL LABS, INC.,	)	
	)	
Petitioner,	)	
	)	
v.	)	
	)	No. <u>22-1123</u>
U.S. FOOD AND DRUG ADMINISTRATION,	)	
	)	
Respondent.	)	
	)	
	)	
	)	

**PUBLIC PETITION FOR REVIEW**

Juul Labs, Inc. (“JLI”) hereby petitions this Court, under 5 U.S.C. § 706, 21 U.S.C. § 387l(a), and Federal Rule of Civil Procedure 15, for review of the U.S. Food and Drug Administration’s June 23, 2022 Marketing Denial Order. The Marketing Denial Order denies JLI’s premarket tobacco product applications for its electronic nicotine delivery system products. A copy of the Marketing Denial Order is attached as Exhibit A.

This Court has jurisdiction and is a proper venue for this action under 21 U.S.C. § 387l(a), which expressly authorizes a person adversely affected by a denial of a premarket tobacco product application to file a petition for judicial review either with this Court or with the court of appeals for the circuit in which such person resides or has their principal place of business, which, for JLI, is also this Court.

Respectfully submitted,

*s/John C. O'Quinn*

JOHN C. O'QUINN

*Counsel of Record*

JASON M. WILCOX

DEVIN S. ANDERSON

KIRKLAND & ELLIS LLP

1301 Pennsylvania Avenue, NW

Washington, DC 20004

(202) 389-5000

john.oquinn@kirkland.com

*Counsel for Petitioner Juul Labs, Inc.*

June 23, 2022

## **CORPORATE DISCLOSURE STATEMENT**

Pursuant to Federal Rule of Appellate Procedure 26.1(a) and Circuit Rule 26.1, Juul Labs, Inc. (a private, nongovernmental party) certifies that it does not have a parent corporation. Atria Group, Inc. owns a minority share of Juul Labs, Inc., and no other publicly held corporation owns 10 percent or more of the stock of Juul Labs, Inc.

**CERTIFICATE OF SERVICE**

I hereby certify that on June 23, 2022, I electronically filed the foregoing with the Clerk of the Court for the United States Court of Appeals for the District of Columbia Circuit by using the CM/ECF system. I also caused the foregoing to be served by electronic mail and first class mail upon:

Robert Califf, Commissioner  
United States Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
robert.califf@fda.hhs.gov

Mark Raza, Chief Counsel  
Office of the Chief Counsel  
United States Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
mark.raza@fda.hhs.gov

Daniel J. Barry, Acting General Counsel  
United States Department of Health and Human Services  
200 Independence Ave., SW, Room 713-F  
Washington, DC 20201-0004  
daniel.barry@hhs.gov

Xavier Becerra, Secretary  
United States Department of Health and Human Services  
200 Independence Ave., SW  
Washington, D.C. 20201-0004  
xavier.becerra@hhs.gov

s/John C. O'Quinn  
John C. O'Quinn

# Exhibit A

**[Confidential Document Filed Under Seal]**